Vertex Announces Data From Two Phase 3 Studies Of INCIVEK. Global Health Completes Phase I For X-Excite. Print E-mail
By Staff   
Wednesday, 22 June 2011 20:10
Below is a look at some of the headlines for companies that made news in the healthcare sector on June 22, 2011.

Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX) announced data from two Phase 3 studies of INCIVEK (telaprevir) tablets, that were published in the New England Journal of Medicine, which showed INCIVEK, combination therapy, significantly improved rates of sustained viral response in a broad group of people with genotype 1 chronic hepatitis C who were new to treatment and those who were treated previously but not cured-relapsers, partial responders and null responders.

Data from these studies, which included nearly 2,000 people, are published in the June 23, 2011 issue of New England Journal of Medicine.


Global Health Ventures Inc. (OTC:GHLV), announced it has completed the clinical trials, a pharmacokinetics (PK) study in Europe under EMEA guideline and the final report has been obtained. In the study, 12 subjects were given 25 mg sildenafil base from Pfizer, oral formulation known as Viagra and another 12 subjects were given 25 mg sildenafil citrate (20.6 mg X-Excite).

The primary objective was the blood pharmacokinetic analysis, maximal drug concentration and time from administration to maximal concentration in plasma (Cmax and Tmax), as well as area under plasma time/concentration curve from zero to eight hours of sildenafil (AUC).

The results in summary, showed, X-Excite to appear in the blood significantly faster than Viagra, stay in the blood longer, and based on actual sildenafil drug used, have a greater AUC. None of the subjects which received X-Excite, dropped out of trials nor any complications were observed. The trials provided the expected and successful end point.

Also Wednesday:

Cepheid (Nasdaq:CPHD) today announced that Robert Kwiatkowski, Ph. D., has joined the company as Vice President of Infectious Disease Research and Development, reporting to David Persing, M.D., Ph.D.

Chembio Diagnostics, Inc. (OTCQB: CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, is providing an update on the revenues anticipated from the Oswaldo Cruz Foundation, ("FIOCRUZ") during the remainder of 2011.

FMI Holdings Ltd. (formerly Forbes Medi-Tech Inc.) (OTCBB:FMTIF) ("FMI" or "Company"), through its liquidator, Abakhan & Associates, Inc., today provided an update with respect to the anticipated timing for completion of the previously-announced liquidation and wind-up of the Company (the "Liquidation").

Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company developing targeted cancer therapies, today announced that it will hold a conference call with the investment community on Wednesday, June 29, 2011 at Noon Eastern (9:00 a.m. Pacific).

GenVec, Inc. (Nasdaq:GNVC) announced that Adel A.F. Mahmoud, M.D., Ph.D. and Edward M. Connor, Jr., M.D. were elected to the Company's Board of Directors at its annual meeting of stockholders held on June 15, 2011.

Insulet Corporation (NASDAQ: PODD) today announced its intention to offer, subject to market and other conditions, $110 million principal amount of convertible senior notes due 2016 (the "notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC") today.

Life Technologies Corporation (NASDAQ:LIFE) today announced that the company has led a successful consortium bid for a Technology Strategy Board grant, in partnership with the Oxford NIHR Biomedical Research Centre, AstraZeneca, and Ortho Biotech Oncology Research & Development unit of Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (ORD).

MiMedx Group, Inc.  (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials including bioimplants processed from human amniotic membrane, announced today that the Company's proprietary device, HydroFix™ Ortho Shield™, has received 510(k) clearance.

Researchers from The Ohio State University, Georgetown University, and Oncolytics Biotech (NASDAQ: ONCY), a Calgary-based biotechnology company, will present a paper on their findings about a type of virus known as the human reovirus, which possesses a remarkable trait: It can replicate inside and kill cancer cells that feature a common mutation (known as an "activated Ras pathway"), while leaving the body's normal cells alone.

Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB), a biotech company with a novel platform technology for the oral delivery of drugs currently only available via injection, announced today that Dr. Michael Berelowitz, M.D., has been appointed the Chairman of its Scientific Advisory Board (SAB).

Sionix Corporation (OTCBB: SINX) ("Sionix"), designer of innovative and patented advanced mobile water treatment systems, today reported successful independent third-party testing results for its Mobile Water Treatment System (MWTS).

Universal Detection Technology (OTCBB: UNDT), a developer of early-warning monitoring technologies that protect against biological, chemical, and radiological threats, announced today that it continues to receive orders for its radiation detection devices for use in Japan and around the world.

Vanguard Health Systems, Inc. (NYSE: VHS) announced today that it will redeem for cash a pro rata portion of its outstanding 10.375% Senior Discount Notes due 2016 (CUSIP No. 922036AD0 and CUSIP No. 92203AC2) (the "Notes"), such pro rata portion being approximately $628.8 million aggregate principal amount at maturity of the Notes (or approximately 84.15% of the original issuance in January 2011 of $747,219,000 aggregate principal amount at maturity of the Notes).

Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leader in advanced wound care solutions today announced that Company President Deborah Jenkins Hutchinson, will present a corporate update at  the 6th annual OneMedForum NY Conference on Thursday, June 23, 2011 at 10 am EDT  held at The Roosevelt Hotel on 45 East 45 St. in New York City.

Zurvita Holdings, Inc. (OTCBB: ZRVT) ("Zurvita" or the "Company"), a dynamic network marketing company offering turn-key solutions for high-quality consumer and business products and services, announced today that it promoted Allen Rejonis to Vice President of Zurvita's new Commercial Division, featuring Zurvita's "ZLinked" business program, which focuses on the trillion dollar online advertising and search directory services market.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus